ストックスクリーナーアプリを入手
701.85
0.90%
-6.40
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Regeneron advances anticoagulant antibody program - The Pharma Letter
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Principal Financial Group Inc. - MarketBeat
REGNRegeneron Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible - GlobeNewswire
Regeneron Will Move Two Factor XI Agents Into Phase III - Citeline News & Insights
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron reports positive results for two anti-coagulant drugs - Seeking Alpha
Regeneron says study data support big bet on new blood thinners - BioPharma Dive
Cutaneous Squamous Cell Carcinoma Market Set to Grow - openPR
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results - The Manila Times
Regeneron To Advance Two Factor Xi Antibodies Into A Broad Phase 3 Program - XM
Regeneron posts Phase 3 win for Eylea HD in retinal vein occlusion - MSN
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month LowHere's Why - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study - Yahoo Finance
Broader Eylea HD label on the cards after Phase III win - The Pharma Letter
Atopic Dermatitis: A Crowded Field With Room To Grow - Citeline News & Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by Canaccord Genuity Group - MarketBeat
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Regeneron to Present at J.P. Morgan Healthcare Conference 2025: Strategic Updates Expected - StockTitan
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease StudyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts - BioSpace
Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Hold Rating from Analysts at Canaccord Genuity Group - MarketBeat
EYLEA HD achieves comparable vision gains with fewer doses - Investing.com
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
Canaccord Genuity Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold Recommendation - MSN
Regeneron, Allele Settle Covid Cocktail Patent Infringement Suit - Bloomberg Law
Allele, Regeneron Settle COVID Treatment Patent Suit - Law360
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year - The Manila Times
Regeneron settles patent lawsuit over protein for testing COVID-19 treatments - Reuters.com
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Galderma’s Nemluvio Brings New Mechanism To Atopic Dermatitis - Citeline
Global EYLEA Drug Market: With CAGR of 7.2% by 20242031 Market - openPR
Lord Abbett & CO. LLC Sells 22,151 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Unloaded Rep. Jonathan L. Jackson - MarketBeat
Regeneron's SWOT analysis: eylea franchise faces challenges as stock navigates pipeline potential - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week LowTime to Sell? - MarketBeat
Oddo BHF Asset Management Sas Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Wilmington Savings Fund Society FSB Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt? - Simply Wall St
Regeneron stock touches 52-week low at $735 amid market shifts - Investing.com Australia
Regeneron Down 15.5% Year to Date: How to Play the Stock? - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Reduced by Franklin Resources Inc. - MarketBeat
Teachers Retirement System of The State of Kentucky Sells 7,517 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Enters Oversold Territory (REGN) - Nasdaq
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma - PharmaVoice
Regeneron Fights Sandoz Eylea Patent-Misconduct Claims (Correct) - Bloomberg Tax
Blankinship & Foster LLC Buys New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Pine Valley Investments Ltd Liability Co Has $5.58 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
42,066 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by World Investment Advisors LLC - MarketBeat
Sanctuary Advisors LLC Sells 9,361 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
6,054 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Virtu Financial LLC - MarketBeat
Toronto Dominion Bank Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
(REGN) On The My Stocks Page - Stock Traders Daily
Regeneron reinstated with an Underperform at BofA - Yahoo Finance
Biotech Roundup: 3 Stocks to Watch - Schaeffers Research
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope - Yahoo Finance
AMGN: 3 Biotech Stocks Revolutionizing Cancer Treatment - StockNews.com
Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects - Insider Monkey
Regeneron Pharmaceuticals (NASDAQ:REGN) Receives "Underperform" Rating from Bank of America - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Geode Capital Management LLC - MarketBeat
Vestcor Inc Has $22.70 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
0.16%
0.35%
大文字化:
|
ボリューム (24 時間):